Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Rises By 25.9%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a significant increase in short interest in December. As of December 15th, there was short interest totaling 17,701 shares, an increase of 25.9% from the November 30th total of 14,057 shares. Based on an average daily trading volume, of 39,649 shares, the short-interest ratio is currently 0.4 days. Approximately 1.3% of the company’s shares are sold short. Approximately 1.3% of the company’s shares are sold short. Based on an average daily trading volume, of 39,649 shares, the short-interest ratio is currently 0.4 days.

Indaptus Therapeutics Price Performance

Shares of NASDAQ:INDP opened at $2.72 on Wednesday. Indaptus Therapeutics has a 1-year low of $1.65 and a 1-year high of $47.60. The business has a fifty day moving average price of $2.55 and a 200-day moving average price of $5.48. The company has a market capitalization of $4.76 million, a PE ratio of -0.09 and a beta of 1.02.

Indaptus Therapeutics (NASDAQ:INDP) last issued its earnings results on Wednesday, November 12th. The company reported ($2.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.17) by $1.19. On average, sell-side analysts anticipate that Indaptus Therapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen lowered Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.